Effects of Cold Atmospheric Plasma (CAP) on Peritoneal Tumor Tissue

Launched by UNIVERSITY HOSPITAL, GHENT · Jan 27, 2025

Keywords

ClinConnect Summary

This clinical trial is studying the effects of a treatment called Cold Atmospheric Plasma (CAP) on tumor tissue in patients with peritoneal metastases, which means their cancer has spread to the lining of the abdomen. The researchers want to find out how different amounts of CAP can affect tumor nodules before they are surgically removed. By treating these nodules and then examining them, the team hopes to learn more about whether CAP can help reduce the vitality of the tumors.

To be eligible for this study, participants must be at least 18 years old and undergoing surgery for peritoneal metastases, regardless of where their cancer started. This includes patients with ovarian cancer, colorectal cancer, or malignant peritoneal mesothelioma. Those interested will need to provide written consent to join the trial. Participants can expect to receive CAP treatment for varying amounts of time before their surgery, and the results will help researchers understand the potential benefits of this innovative approach in cancer treatment.

Gender

ALL

Eligibility criteria

• Inclusion criteria:
• • Patients with peritoneal metastases undergoing surgery (CRS, debulking), irrespective of the origin. Potential cancer types include ovarian cancer, colorectal cancer, and malignant peritoneal mesothelioma
• • Written informed consent
• • Age ≥ 18 years.